Lurasidone

Course Summary

Lurasidone (Latuda) is an atypical, second-generation antipsychotic that has labeled uses for treating bipolar disorder, major depressive disorder, and schizophrenia. It is approved for the treatment of schizophrenia in adults and adolescents (13 to 17 years) with schizophrenia. It is also used as a monotherapy to treat adults, children and teens (10 to 17 years) with depressive episodes that happen with bipolar I disorder or bipolar depression. Lurasidone has been approved as an adjunctive therapy with lithium or valproic acid. Lurasidone’s precise mechanism of action is unknown. It is believed to rebalance dopamine and serotonin to improve thinking, mood, and behavior. Contraindication of lurasidone use includes co-administration with strong CYP3A4 inhibitors (such as, ketoconazole, clarithromycin), as well as co-administration with strong CYP3A4 inducers (such as, St. John’s wort, phenytoin, carbamazepine, and rifampin).